Traduction de «new antiinfective drugs for » (Français → Néerlandais) :

Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. General guidelines for the evaluation of new antiinfective drugs for the treatment of urinary tract infection.
Evaluation of new anti-infective drugs for the treatment of urinary tract infection.

General guidelines for the evaluation of new antiinfective drugs for the treatment of urinary tract infection.
A practical approach to diagnosing and treating urinary tract infections in adults.

[La Revue Prescrire 1999; 19:518-9; New Engl J Med 2006; 354:158-65; Drug Safety 2001; 24:921- 7; Drugs 2004; 64:2503-14; Fiche de transparence «Antimigraineux», janvier 2003 avec mises à jour; le «Projet Information Orale Indépendante sur le Médicament» (SSMG/SSPF) a publié, sous l’égide du CBIP, le document intitulé «Les médicaments anti-céphalalgiques»]
[La Revue Prescrire 1999; 19:518-9 ; New Engl J Med 2006; 354:158-65 ; Drug Safety 2001; 24:921- 7 ; Drugs 2004; 64:2503-14 ; Transparantiefiche «Geneesmiddelen bij migraine», januari 2003 met updates); het «Projet Information Orale Indépendante sur le Médicament» (SSMG/SSPF) publiceerde, onder de auspiciën van het BCFI, het document «Les médicaments anti-céphalalgiques»]

États-Unis, une New Drug Application (NDA) est introduite auprès de la Food and Drug Administration (FDA) américaine.
te mogen brengen. In de VS wordt er een New Drug Application (NDA) ingediend bij de Amerikaanse Food and Drug Administration (FDA).

Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.
This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.

Therapeutics Letter, June-September 2002 (via [http ...]
Therapeutics letter, june-september 2002 (via [http ...]

Leukotriene antagonists: new drugs for astma.
Leukotriene antagonists new drugs for astma .

“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis.
“Pfizer’s commitments build on our ongoing efforts to fight neglected tropical diseases, which includes the work done through our support of the International Trachoma Initiative, by our colleagues who participate in our Global Health Fellows program, and through our participation in WIPO Re: Search -- a publicprivate consortium for sharing intellectual property and expertise with the global health research community to promote the development of new drugs, vaccines and diagnostics for the treatment of neglected tropical diseases, malaria and tuberculosis. “We are proud to be a part of this innovative effort to support a healthier world”.

Récemment, l’attention a été attirée dans le New England Journal of Medicine [2007; 356:1601-4 et 1675-6] ainsi que dans la presse destinée au grand public sur une étude américaine avec la télithromycine (débutée en 2001): les inspecteurs de la Food and Drug Administration (FDA) américaine ont dénoncé que, dans une étude destinée à mieux définir le profil d’effets indésirables de la télithromycine, des patients fictifs aient été inclus dans plusieurs centres d’étude.
Recent werd in de New England Journal of Medicine [2007; 356:1601-4 en 1675-6] alsook in de lekenpers, aandacht besteed aan een Amerikaanse studie met telithromycine (gestart in 2001): inspecteurs van de Amerikaanse Food and Drug Administration (FDA) brachten aan het licht dat bij een studie met als doel het profiel van ongewenste effecten van telithromycine beter te definiëren, in een aantal onderzoekscentra fictieve patiënten waren ingesloten.